IMDXInsight Molecular Diagnostics Inc.同业对比
Insight Molecular Diagnostics Inc. 与SIC 2835 行业的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 | 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IMDX本股 | $94M#8 | — | — | 23.2x#8 | 115.6%#1 | 17.2%#8 | -1260.8%#8 | — | — | — | -53.0%#10 | — |
| CLDX | $2.3B#1 | — | 3.3x#8 | 1506.5x#11 | -78.0%#11 | -63.9%#11 | -18599.8%#9 | -36.2%#2 | — | — | 19.8%#4 | — |
| NTLA | $1.7B#2 | — | 2.3x#7 | 25.0x#9 | 16.9%#3 | 20.5%#7 | -651.7%#6 | -56.7%#3 | — | — | -7.8%#6 | — |
| QDEL | $948M#3 | — | 0.5x#3 | 0.3x#1 | -1.9%#6 | 44.8%#2 | -33.7%#1 | -63.8%#4 | -19.5%#1 | — | -50.1%#9 | — |
| ACHV | $690M#4 | — | — | — | — | -37.2%#10 | — | — | — | — | 31.3%#3 | — |
| MYGN | $566M#5 | — | 1.9x#5 | 0.7x#2 | -1.6%#5 | -188.2%#12 | -47.0%#3 | -120.4%#9 | -76.1%#4 | — | -27.6%#7 | — |
| TKNO | $391M#6 | — | 6.3x#9 | 9.7x#7 | 7.4%#4 | 35.5%#3 | -41.9%#2 | -27.6%#1 | -25.2%#2 | 5#1 | 43.5%#2 | — |
| ICCC | $95M#7 | — | — | — | — | — | — | — | — | — | 68.6%#1 | — |
| BMRA | $8M#9 | — | 2.2x#6 | 1.8x#4 | -16.2%#8 | 24.1%#4 | -119.5%#4 | -103.5%#8 | — | — | -36.4%#8 | — |
| CDIO | $5M#10 | — | 0.7x#4 | 329.4x#10 | -57.5%#9 | 22.5%#5 | -43737.5%#10 | -87.5%#6 | — | — | -62.5%#11 | — |
| QCLS | $3M#11 | 0.0x#1 | 0.2x#2 | 2.2x#5 | -5.3%#7 | 50.2%#1 | -624.4%#5 | -72.3%#5 | -61.2%#3 | — | -87.4%#12 | — |
| VNRX | $3M#12 | — | — | 1.5x#3 | 40.0%#2 | 13.4%#9 | -1258.5%#7 | — | — | — | -97.8%#13 | — |
| CDIOW | $40249#13 | — | 0.0x#1 | 2.7x#6 | -57.5%#9 | 22.5%#5 | -43737.5%#10 | -87.5%#6 | — | — | -0.7%#5 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 本表构建超时,仅覆盖该组的一部分成员;排名仅相对于已列出的行,稍后会自动补全。 数据构建于 2026-11-04。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议